NO123427B - - Google Patents
Download PDFInfo
- Publication number
- NO123427B NO123427B NO16631467A NO16631467A NO123427B NO 123427 B NO123427 B NO 123427B NO 16631467 A NO16631467 A NO 16631467A NO 16631467 A NO16631467 A NO 16631467A NO 123427 B NO123427 B NO 123427B
- Authority
- NO
- Norway
- Prior art keywords
- phenylcyclohexylamine
- trans
- acid
- salts
- biphenylyl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 claims description 20
- SJISCEAZUHNOMD-UHFFFAOYSA-N 4-phenylcyclohexan-1-amine Chemical class C1CC(N)CCC1C1=CC=CC=C1 SJISCEAZUHNOMD-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000012442 inert solvent Substances 0.000 claims description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000000114 Pain Threshold Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000037040 pain threshold Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- JALUUBQFLPUJMY-UHFFFAOYSA-N 2-(4-phenylphenyl)propanoic acid Chemical class C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 JALUUBQFLPUJMY-UHFFFAOYSA-N 0.000 description 3
- -1 4-biphenylyl Chemical group 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- IYEPZNKOJZOGJG-UHFFFAOYSA-N xenbucin Chemical class C1=CC(C(C(O)=O)CC)=CC=C1C1=CC=CC=C1 IYEPZNKOJZOGJG-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- JTLAHVRPWDIEMU-UHFFFAOYSA-N n-(4-phenylcyclohexylidene)hydroxylamine Chemical compound C1CC(=NO)CCC1C1=CC=CC=C1 JTLAHVRPWDIEMU-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LGJWPXGDZJETQK-UHFFFAOYSA-N 4-(2-phenylphenyl)butanoic acid Chemical compound OC(=O)CCCC1=CC=CC=C1C1=CC=CC=C1 LGJWPXGDZJETQK-UHFFFAOYSA-N 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- SJISCEAZUHNOMD-HAQNSBGRSA-N C1C[C@@H](N)CC[C@@H]1C1=CC=CC=C1 Chemical class C1C[C@@H](N)CC[C@@H]1C1=CC=CC=C1 SJISCEAZUHNOMD-HAQNSBGRSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 150000003946 cyclohexylamines Chemical class 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- TXTHKGMZDDTZFD-UHFFFAOYSA-N n-cyclohexylaniline Chemical class C1CCCCC1NC1=CC=CC=C1 TXTHKGMZDDTZFD-UHFFFAOYSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Fremgangsmåte til fremstilling av terapeutisk virksomme Process for the production of therapeutically active
salter av trans 4-fenylcykloTieksylamin med en a (4-bifenylyl) - lavere alkansyre. salts of trans 4-phenylcycloThiexylamine with an a (4-biphenylyl)-lower alkanoic acid.
Foreliggende oppfinnelse vedrorer en fremgangsmåte til fremstilling av anti-inflammatorisk og analgetisk virksomme salter av trans 4_fenylcykloheksylamin med <x(4-bifenylyl)-lavere alkansyrer med den generelle formel: The present invention relates to a process for the preparation of anti-inflammatory and analgesic active salts of trans 4-phenylcyclohexylamine with <x(4-biphenylyl)-lower alkanoic acids with the general formula:
hvor R betyr en alkylgruppe med 1-4 karbonatomer. where R means an alkyl group with 1-4 carbon atoms.
Fenylcykloheksylaminsalter av oc(4-bifenylyl)propionsyre og av a(4-bifenylyl)-smorsyre er blitt fremstilt og har vist seg å være meget aktive, ikke-toksiske og pålitelige analgetiske og anti-inflamma-toriske midler. Phenylcyclohexylamine salts of α(4-biphenylyl)propionic acid and α(4-biphenylyl)butyric acid have been prepared and have been shown to be highly active, non-toxic and reliable analgesic and anti-inflammatory agents.
Fra belgisk patent nr. 664 187 er det kjent anti-inflammatorisk aktive preparater hvilke som aktiv bestanddel inneholder 4-fenyl-oc-metylfenyl-eddiksyre, eller salter, estere og amider derav. From Belgian patent no. 664 187, anti-inflammatory active preparations are known which contain as active ingredient 4-phenyl-oc-methylphenyl-acetic acid, or salts, esters and amides thereof.
Fra fransk patent nr. 2 401 M er det kjent analgetisk virksomme salter dannet av en substituert aminalkohol og en syre med formelen: From French patent no. 2 401 M, analgesically active salts formed from a substituted amine alcohol and an acid with the formula are known:
hvor R-^er en lavere alkylgruppe. where R-1 is a lower alkyl group.
De ifolge foreliggende oppfinnelse fremstilte salter har en terapeutisk virkning som er sterkere enn den til de ovenfor omtalte kjente midler og har ikke ubehagelige og uonskede bivirkninger. The salts produced according to the present invention have a therapeutic effect which is stronger than that of the above-mentioned known agents and do not have unpleasant and unwanted side effects.
Ifolge foreliggende oppfinnelse fremstilles de nevnte salter ved at ekvimolekylære mengder av syren og aminet opploses i separate mengder av inerte opplosningsmidler, den ene opplosning tilsettes til den andre og det således tilveiebragte salt oppsamles. According to the present invention, the aforementioned salts are prepared by dissolving equimolecular amounts of the acid and the amine in separate amounts of inert solvents, one solution is added to the other and the salt thus provided is collected.
I det folgende eksempel 1 er den direkte fremstilling av ren trans 4-fenylcykloheksylamin som er fri for cis-isomeren, beskrevet som illustrasjon. In the following example 1, the direct preparation of pure trans 4-phenylcyclohexylamine, which is free of the cis isomer, is described as an illustration.
F. ksempel 1 Direkte fremstilling av " trans" 4- fenylcykloheksylamin. Example 1 Direct preparation of "trans" 4-phenylcyclohexylamine.
400 g findelt elementært natrium tilsettes i lopet av 2 timer til en kokende opplosning av 302.7 g fl.6 moll 4-fenylcykloheksanonoksim i 3*2 1 absolutt etanol. Blandingen kokes under til-bakelop i ytterligere 1 time slik at alt natrium opploses fullstendig og etter dekantering inndampes blandingen til torrhet under redusert trykk. 400 g of finely divided elementary sodium is added over the course of 2 hours to a boiling solution of 302.7 g fl.6 mol 4-phenylcyclohexanone oxime in 3*2 1 absolute ethanol. The mixture is boiled under reflux for a further 1 hour so that all the sodium dissolves completely and after decantation the mixture is evaporated to dryness under reduced pressure.
Resten tas opp i 2 1 vann og gjores sur overfor Kongorodt med 20 % HC1. neretter tilsettes 2 1 eter og suspensjonen omrores i 30 minutter, idet aminhydrokloridet separeres for således å bli opp-samlet og krystallisert i 2 1 vann. The residue is taken up in 2 1 of water and acidified against Kongorodt with 20% HC1. 2 1 of ether are then added and the suspension is stirred for 30 minutes, the amine hydrochloride being separated so as to be collected and crystallized in 2 1 of water.
Utbytte: 250 g f74 % av det teoretiske) smeltepunkt 338<0>- 340°C. Yield: 250 g f74% of the theoretical) melting point 338<0>- 340°C.
Det således tilveiebragte hydroklorid suspenderes i en skilletrakt i 2.5 1 2N NaOH og 2.5 1 eter. Det faste stoffet opploses gradvis ved kraftig rysting av trakten. Det eteriske ekstrakt separeres og væsken ekstraheres igjen to ganger med eter, idet de to ekstraktene kombineres med det forste. The hydrochloride thus obtained is suspended in a separatory funnel in 2.5 1 2N NaOH and 2.5 1 ether. The solid substance is gradually dissolved by vigorous shaking of the funnel. The ethereal extract is separated and the liquid is extracted again twice with ether, the two extracts being combined with the first.
Den eteriske opplosning torkes ved rysting med vannfritt natriumsulfat og NaOH, og filtreres. Filterkaken består hovedsakelig av karbonerte aminer, ettersom cykloheksylaminer er meget reaktive med atmosfærisk karbondioksyd. De kombinerte eteriske ekstrakter inndampes under en strom av nitrogen og resten destilleres under redusert trykk i nitrogenstrom, hvilket gir 208 g av den onskede trans 4-fenylcykloheksylamin, kokepunkt 131°C under 16 mm Hg, smeltepunkt 54° - 55°^. Analyse av forbindelsen: The ethereal solution is dried by shaking with anhydrous sodium sulfate and NaOH, and filtered. The filter cake consists mainly of carbonated amines, as cyclohexylamines are highly reactive with atmospheric carbon dioxide. The combined ethereal extracts are evaporated under a stream of nitrogen and the residue is distilled under reduced pressure in a stream of nitrogen, yielding 208 g of the desired trans 4-phenylcyclohexylamine, boiling point 131°C under 16 mm Hg, melting point 54°-55°^. Analysis of the compound:
Ved hjelp av foregående fremgangsmåte er det således mulig With the help of the preceding method, it is thus possible
å tilveiebringe "trans" formen av 4-fenylcykloheksylamin direkte, mens derimot den andre fremgangsmåten f.eks. den katalytiske hydrogenering av 4-fenylcykloheksanonoksim ga en blanding av "cis— og "trans"-stereoisomerene, idet nevnte blanding deretter måtte separeres ved å gå om N-benzoylderivatene for å gjenvinne den onskede stereoisomer. to provide the "trans" form of 4-phenylcyclohexylamine directly, while on the other hand the other method e.g. the catalytic hydrogenation of 4-phenylcyclohexanone oxime gave a mixture of the "cis" and "trans" stereoisomers, said mixture then having to be separated by bypassing the N-benzoyl derivatives to recover the desired stereoisomer.
Hvis stoffet som tilveiebringes på den ovenfor omtalte måten kromatograferes på et tynt lag av silisiumdioksydgel (ved bruk av en opplosning av etanol-25% ammoniakk i forholdet 95-5 som opplosnings-middell, observeres faktisk bare en flekk ved dusjing med ninhydrin, mens det med stoffet som tilveiebringes ved katalytisk hydrogenering observeres to flekker. If the substance obtained in the manner described above is chromatographed on a thin layer of silica gel (using a solution of ethanol-25% ammonia in the ratio 95-5 as the solvent), only one spot is actually observed when douching with ninhydrin, while with the substance provided by catalytic hydrogenation, two spots are observed.
Folgende tabell gir en oversikt over de mest betydnings-fulle fysiske og kjemiske data for saltene av trans 4-fenylcykloheksylamin : The following table provides an overview of the most significant physical and chemical data for the salts of trans 4-phenylcyclohexylamine:
De folgende eksempler illustrerer fremgangsmåten for til-veiebringelse av saltene som er oppfort i ovenstående tabell. Eksempler 2 og 3 Fremstilling av trans 4- fenylcykloheksylaminsaltene av a( 4- bifenylyl) propionsyre og a( 4- bifenylyl) smor-syre. The following examples illustrate the method for preparing the salts listed in the above table. Examples 2 and 3 Preparation of the trans 4-phenylcyclohexylamine salts of α(4-biphenylyl)propionic acid and α(4-biphenylyl)butric acid.
Siden fremgangsmåten er den samme for saltene av de to syrer, folger en generell beskrivelse. Since the procedure is the same for the salts of the two acids, a general description follows.
0.02 mol av den valgte syren (dvs. 4«52 g 4-bifenylyl-propionsyre; eller alternativt 4-80 g 4~bifenylyl-smorsyre) opploses i 100 ml aceton og oppløsningen tilsettes til en opplosning av 0.02 mol (3«5 g) trans 4-fenylcykloheksylamin i 20 ml kokende aceton. 0.02 mol of the selected acid (ie 4-52 g of 4-biphenylyl-propionic acid; or alternatively 4-80 g of 4-biphenylyl-butyric acid) is dissolved in 100 ml of acetone and the solution is added to a solution of 0.02 mol (3-5 g ) trans 4-phenylcyclohexylamine in 20 ml of boiling acetone.
Det dannes et bunnfall og reaksjonsblandingen kokes i ytterligere 2 timer under omroring og filtreres mens den ennå er varm. Resten oppslemmes i 100 ml varm aceton, denne oppsiemming filtreres igjen og vaskes noen ganger med aceton. A precipitate forms and the reaction mixture is boiled for a further 2 hours with stirring and filtered while still hot. The residue is suspended in 100 ml of hot acetone, this suspension is filtered again and washed a few times with acetone.
Den betennelseshemmende og analgetiske aktivitet til stoff-ene er undersokt ved forsok på rotter ved å måle netto okning i smerte-terskelverdi i dyrenes betente poter, idet fremgangsmåten var den som er beskrevet av Randall og Selitto, Arch. Int. Pharmacodyn., 111 409 f 195<7>K The anti-inflammatory and analgesic activity of the substances has been investigated in experiments on rats by measuring the net increase in pain threshold value in the animals' inflamed paws, the procedure being that described by Randall and Selitto, Arch. Int. Pharmacodyn., 111 409 f 195<7>K
Saltet av trans 4-fenylcykloheksylamin med a(4-bifenylyl)-smorsyre var aktivt i doser fra 5 mg per kg kroppsvekt og smerte-terskelverdien ble oket ved doser på 20 mg per kg kroppsvekt (per os); idet varigheten av virkningene ble korrelert med dosen. The salt of trans 4-phenylcyclohexylamine with α(4-biphenylyl)-butyric acid was active in doses from 5 mg per kg body weight and the pain threshold value was increased at doses of 20 mg per kg body weight (per os); as the duration of the effects was correlated with the dose.
Gjennomsnittsverdien for smerte-terskelverdien (på 20 dyr) etter 2 timer i den betente poten på ubehandlede (kontroll) dyr, er omtrent 60 mm Hg og dosen av den forbindelse som forårsaker en heving på 100 % av smerte-terskelverdien (dvs. ytterligere 60 mm Hg), er ca. 8 mg per kg kroppsvekt, sammenlignet med 120 - 170 mg per kg kroppsvekt, som er den mengde som kreves for å oppnå den samme heving av smerte-terskelverdien under anvendelse av fenylbutazon og aminopyrin. The average pain threshold value (of 20 animals) after 2 hours in the inflamed paw of untreated (control) animals is approximately 60 mm Hg and the dose of the compound causing a 100% elevation of the pain threshold (ie, an additional 60 mm Hg), is approx. 8 mg per kg of body weight, compared to 120 - 170 mg per kg of body weight, which is the amount required to achieve the same elevation of pain threshold using phenylbutazone and aminopyrine.
Det nye som oppnåes ved foreliggende oppfinnelse er at en a-lavere alkyl-4-fenyl-fenyleddiksyre sammen med trans-4-fenylcykloheksylamin gir et salt hvis analgetiske aktivitet mot smerter av inflammatorisk opprinnelse (undersokt ifolge et forsok av Randall og Selitto)' er meget sterkere enn det som kunne ha vært ventet ut fra en undersokelse av de terapeutiske aktiviteter til de to enkeltkomponen-ter (kfr. "Il Farmaco" Scientific Edition, 24 (140) (I969) sidene 143-144<1.>The new thing achieved by the present invention is that an α-lower alkyl-4-phenyl-phenylacetic acid together with trans-4-phenylcyclohexylamine gives a salt whose analgesic activity against pain of inflammatory origin (investigated according to an experiment by Randall and Selitto)' is much stronger than what could have been expected from an investigation of the therapeutic activities of the two individual components (cf. "Il Farmaco" Scientific Edition, 24 (140) (1969) pages 143-144<1.>
o I nedenstående tabell angis resultatene fra en sammenlig-ning mellom aktivitetene til enkeltkomponentene og til salter fremstilt ifolge foreliggende oppfinnelse. For hver forbindelse angis de effektive doseringer som skal til for å gi en aktivitetsøkning på 50 % (ED^Q-verdien) og på 100 % (ED-^qq-verdien) utarbeidet ifolge Randall's og Selitto's forsok på rotter, idet doseringsmengden er ut-trykt i mikromol per kg legemsvekt, administrert oralt. o In the table below, the results from a comparison between the activities of the individual components and of salts produced according to the present invention are given. For each compound, the effective dosages required to produce an activity increase of 50% (ED^Q value) and of 100% (ED-^qq value) are given, prepared according to Randall's and Selitto's experiments on rats, the dosage amount being out -printed in micromoles per kg body weight, administered orally.
De ovenfor angitte data viser tydelig at saltet av 4-fenyl-a-etyl-fenyleddiksyre med trans-4-fenylcykloheksylamin er to ganger mer aktivt enn den tilsvarende mengde av den i saltet tilstedeværende syre og fra 10 til 15 ganger mer aktivt enn det i saltet tilstedeværende amin. The above data clearly show that the salt of 4-phenyl-α-ethyl-phenylacetic acid with trans-4-phenylcyclohexylamine is twice as active as the corresponding amount of the acid present in the salt and from 10 to 15 times more active than that in the salt present amine.
I tillegg til dette gis det ifolge oppfinnelsen fremstilte 4-fenylcykloheksylaminsaltet en nedsatt vekst av granuloma forårsaket ved implantering av bomullspellets; en nedsettelse som er meget stdrre enn den som oppnåes med de to komponenter tatt hver for seg, slik at det oppnåes en vesentlig anti-inflammatorisk effekt i tillegg til den analgetiske effekt (kfr. "Il Farmaco", tabell VI, side 150), In addition to this, the 4-phenylcyclohexylamine salt produced according to the invention reduces the growth of granuloma caused by implantation of cotton pellets; a reduction that is much greater than that achieved with the two components taken separately, so that a significant anti-inflammatory effect is achieved in addition to the analgesic effect (cf. "Il Farmaco", table VI, page 150),
Saltdannelsen med 4-trans-fenylcykloheksylamin har således The salt formation with 4-trans-phenylcyclohexylamine thus has
en uventet og ikke åpenbar virkningsokning når det gjelder aktivitetene til enkeltkomponentene (syren og aminet). En slik okning i effekt observeres ikke med saltene av andre aminer slik som de som er beskrevet i det ovennevnte belgiske patent nr. 664 187 og det ovennevnte franske patent nr. 2401 M. an unexpected and not obvious increase in effectiveness in terms of the activities of the individual components (the acid and the amine). Such an increase in effect is not observed with the salts of other amines such as those described in the above-mentioned Belgian Patent No. 664,187 and the above-mentioned French Patent No. 2401 M.
Claims (1)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1339866 | 1966-01-14 | ||
IT1952966 | 1966-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO123427B true NO123427B (en) | 1971-11-15 |
Family
ID=26326642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO16631467A NO123427B (en) | 1966-01-14 | 1967-01-09 |
Country Status (7)
Country | Link |
---|---|
BE (1) | BE692583A (en) |
DE (1) | DE1618632B1 (en) |
DK (1) | DK126107B (en) |
ES (1) | ES335177A1 (en) |
GR (1) | GR33295B (en) |
NO (1) | NO123427B (en) |
SE (1) | SE324764B (en) |
-
1966
- 1966-12-30 DK DK677866A patent/DK126107B/en unknown
-
1967
- 1967-01-02 ES ES0335177A patent/ES335177A1/en not_active Expired
- 1967-01-09 NO NO16631467A patent/NO123427B/no unknown
- 1967-01-10 GR GR670133295A patent/GR33295B/en unknown
- 1967-01-11 DE DE1967M0072375 patent/DE1618632B1/en active Pending
- 1967-01-11 SE SE40867A patent/SE324764B/xx unknown
- 1967-01-13 BE BE692583D patent/BE692583A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ES335177A1 (en) | 1967-11-16 |
DK126107B (en) | 1973-06-12 |
SE324764B (en) | 1970-06-15 |
GR33295B (en) | 1967-11-21 |
DE1618632B1 (en) | 1971-11-11 |
BE692583A (en) | 1967-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3067101A (en) | Method for controlling hypertension | |
Freudenberg et al. | Study on the Configuration of EPHEDRINE1 | |
DE2463219C2 (en) | ||
DE2202728A1 (en) | Substituted indensic acids | |
DE69414194T2 (en) | Amino acid derivatives and their use as enkephalinase inhibitors | |
EP0005559B1 (en) | Phenylaminothiophene acetic acids, process for their preparation and medicaments containing them | |
DE2044172C3 (en) | Pyrrole derivatives, a process for their preparation and pharmaceuticals | |
DE2511647A1 (en) | NEW BENZOPYRAND DERIVATIVES | |
NO123427B (en) | ||
EP0012801B1 (en) | 2-(1-phenyl-2,5-cyclohexadienyl)-ethylamine derivatives, process for their preparation, their use as active pharmaceutical agents and pharmaceutical compositions containing them | |
DE2202715A1 (en) | Substituted indenyl acetic acids | |
US3153050A (en) | Spiro | |
BURGER et al. | 2-Phenylcyclobutanecarboxylic Acid1 | |
DE2039426B2 (en) | ||
DE1618817C3 (en) | 17-ethers of 4,9,11-gona-trienes, processes for their preparation and pharmaceutical formulations containing them | |
US3719713A (en) | Fluorinated beta-phenyl-alpha-methylethylamines | |
Sunko et al. | Studies in the Sphingolipids Series. II. Synthesis of Enantiomeric Sphingines | |
NO137893B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE 1-M-TRIFLUOROMETHYLPHENYL-2-CYANOALKYLAMINOPROPANES | |
DE2804837C2 (en) | Medicines based on cysteinol and homocysteinol derivatives | |
DE2263817A1 (en) | ORGANIC COMPOUNDS | |
NO121344B (en) | ||
DE2234706A1 (en) | DERIVATIVES OF 9-OXO-13-TRANS-PROSTIC ACID ESTERS | |
US3799982A (en) | N-(beta,beta-difluoro,alpha-methylphenethyl)-formamide | |
DE2337120A1 (en) | 4,5,6 OR 7-INDENYL ACIDS | |
DE2934508A1 (en) | ALPHA -ALKYL-O-OXYBENZYLAMINE DERIVATIVES, THEIR PRODUCTION AND REMEDIES CONTAINING THEM |